FDA Brief

Warning letters Drugs

FDA warning letter to

Maison Blanche LLC

MediumIssued Sep 14, 2023Posted Sep 19, 2023Center for Drug Evaluation and Research | CDER

FDA warns Maison Blanche for refusing repeated requests for records on its OTC hand sanitizer.

What happened

FDA sent electronic requests for records and other information under section 704(a)(4) on August 16 and August 31, 2022, to the email in Maison Blanche's registration file. The firm did not answer those requests or later FDA emails and phone messages, including messages in September 2023 asking for a response within 24 hours. FDA said it has no indication of the quality assurance for drugs registered as manufactured at the firm's facility.

What FDA found

  1. The company did not provide FDA with records and other information it requested about its OTC drug manufacturing.

    Section 704(a)(4) of the FD&C Act (21 U.S.C. 374(a)(4))
  2. FDA says refusing to permit access to or copying of required records is a prohibited act.

    Section 301(e) of the FD&C Act (21 U.S.C. 331(e))

What FDA wants

Respond within 48 hours to confirm or update the firm's registration and drug listing status and to say whether it will respond to the records request. If it no longer makes drugs, delist all previously listed drugs using the last lot expiration date as the marketing end date and deregister the facility.

Who should pay attention

  • retailers and distributors that sell Hand Sanitizer Nº93 Maison Blanche
  • companies that rely on FDA drug listing and registration records for supplier checks
  • OTC drug manufacturers with unanswered FDA records requests

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Chongqing Qiancan Technology Co., Ltd.

    Chongqing Qiancan Technology, an API maker in China, refused FDA records requests; FDA placed its drugs on import alert 66-79.

    High risk
  2. Zenzi Pharmaceutical Industries Pvt. Ltd.

    Zenzi Pharmaceutical Industries refused FDA requests for records about prescription drugs made for the U.S. market.

    High risk
  3. Wipro Unza Singapore Private, Limited

    FDA cites Wipro Unza Singapore for refusing OTC hand sanitizer records, leading to import alert.

    High risk
  4. Gulf States International, Inc.

    Gulf States International refused FDA requests for OTC drug manufacturing records, FDA says.

    Medium